JP2008512394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512394A5 JP2008512394A5 JP2007530543A JP2007530543A JP2008512394A5 JP 2008512394 A5 JP2008512394 A5 JP 2008512394A5 JP 2007530543 A JP2007530543 A JP 2007530543A JP 2007530543 A JP2007530543 A JP 2007530543A JP 2008512394 A5 JP2008512394 A5 JP 2008512394A5
- Authority
- JP
- Japan
- Prior art keywords
- substance
- epha4
- antagonist
- receptor
- rnai
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000021727 EphA4 Receptor Human genes 0.000 claims 16
- 108010055179 EphA4 Receptor Proteins 0.000 claims 16
- 239000000126 substance Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 13
- 108091030071 RNAI Proteins 0.000 claims 8
- 230000009368 gene silencing by RNA Effects 0.000 claims 8
- 206010018341 Gliosis Diseases 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 102000050554 Eph Family Receptors Human genes 0.000 claims 5
- 108091008815 Eph receptors Proteins 0.000 claims 5
- 229940122293 Ephrin antagonist Drugs 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000007387 gliosis Effects 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 230000003376 axonal effect Effects 0.000 claims 3
- 206010061431 Glial scar Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 230000009036 growth inhibition Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004905148A AU2004905148A0 (en) | 2004-09-08 | A method of treatment and agents useful for same | |
| AU2004905148 | 2004-09-08 | ||
| US64796805P | 2005-01-27 | 2005-01-27 | |
| US60/647,968 | 2005-01-27 | ||
| PCT/AU2005/001363 WO2006026820A1 (en) | 2004-09-08 | 2005-09-08 | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012030227A Division JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008512394A JP2008512394A (ja) | 2008-04-24 |
| JP2008512394A5 true JP2008512394A5 (https=) | 2008-10-09 |
| JP5094395B2 JP5094395B2 (ja) | 2012-12-12 |
Family
ID=36036018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530543A Expired - Fee Related JP5094395B2 (ja) | 2004-09-08 | 2005-09-08 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
| JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080254023A1 (https=) |
| EP (1) | EP1793854A4 (https=) |
| JP (2) | JP5094395B2 (https=) |
| CA (1) | CA2579352A1 (https=) |
| NZ (1) | NZ553273A (https=) |
| WO (1) | WO2006026820A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| WO2006026820A1 (en) * | 2004-09-08 | 2006-03-16 | The University Of Queensland | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
| EP2043638A2 (en) * | 2006-07-13 | 2009-04-08 | Novartis AG | Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders |
| US8530181B2 (en) | 2007-11-15 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase |
| US7892769B2 (en) * | 2007-11-30 | 2011-02-22 | Eisai R&D Management Co., Ltd. | Processing of EphA4 polypeptide by γ-secretase activity |
| EP2260864A1 (en) * | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
| JP6059017B2 (ja) | 2010-12-17 | 2017-01-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法 |
| EP2703814B1 (en) | 2011-04-25 | 2017-11-01 | Eisai R&D Management Co., Ltd. | Method for detecting neurological disease associated with cognitive dysfunction by measuring epha4 extracellular domain |
| US10322161B2 (en) | 2014-07-15 | 2019-06-18 | Sanford Burnham Prebys Medical Discovery Institute | EPHA4 cyclic peptide antagonists for neuroprotection and neural repair |
| RU2651756C1 (ru) * | 2017-05-10 | 2018-04-23 | Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ | Препарат для предотвращения образования глиальных рубцов |
| AR119303A1 (es) | 2019-07-01 | 2021-12-09 | Eisai R&D Man Co Ltd | Anticuerpo anti-epha4 humano |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP674898A0 (en) * | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| DE69925024T2 (de) * | 1998-11-20 | 2006-03-02 | Genentech, Inc., South San Francisco | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten |
| WO2004028551A1 (en) * | 2002-09-24 | 2004-04-08 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| US20040147469A1 (en) * | 2002-11-01 | 2004-07-29 | Case Western Reserve University | Methods of inhibiting glial scar formation |
| WO2005056766A2 (en) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES |
| WO2006026820A1 (en) * | 2004-09-08 | 2006-03-16 | The University Of Queensland | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
-
2005
- 2005-09-08 WO PCT/AU2005/001363 patent/WO2006026820A1/en not_active Ceased
- 2005-09-08 NZ NZ553273A patent/NZ553273A/en not_active IP Right Cessation
- 2005-09-08 EP EP05778955A patent/EP1793854A4/en not_active Withdrawn
- 2005-09-08 JP JP2007530543A patent/JP5094395B2/ja not_active Expired - Fee Related
- 2005-09-08 CA CA002579352A patent/CA2579352A1/en not_active Abandoned
- 2005-09-08 US US11/662,355 patent/US20080254023A1/en not_active Abandoned
-
2012
- 2012-02-15 JP JP2012030227A patent/JP2012136529A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mecca et al. | Cerebroprotection by angiotensin‐(1–7) in endothelin‐1‐induced ischaemic stroke | |
| Knoll et al. | Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats | |
| Million et al. | CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats | |
| Arborelius et al. | Increased responsiveness of presumed 5-HT cells to citalopram in adult rats subjected to prolonged maternal separation relative to brief separation | |
| Daenen et al. | Adaptation and habituation to an open field and responses to various stressful events in animals with neonatal lesions in the amygdala or ventral hippocampus | |
| JP2008512394A5 (https=) | ||
| Beamer et al. | N w‐Propyl‐l‐arginine (L‐NPA) reduces status epilepticus and early epileptogenic events in a mouse model of epilepsy: behavioural, EEG and immunohistochemical analyses | |
| Klausner et al. | The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat | |
| Brait et al. | Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome | |
| Ebbinghaus et al. | The anti-inflammatory effects of sympathectomy in murine antigen-induced arthritis are associated with a reduction of Th1 and Th17 responses | |
| Desai et al. | A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors | |
| Feng et al. | Activation of guanylate cyclase-C attenuates stretch responses and sensitization of mouse colorectal afferents | |
| Manjavachi et al. | The role of keratinocyte-derived chemokine (KC) on hyperalgesia caused by peripheral nerve injury in mice | |
| Zychowska et al. | Spinal CCL1/CCR8 signaling interplay as a potential therapeutic target–evidence from a mouse diabetic neuropathy model | |
| Abraham et al. | β1-and β2-adrenoceptor induced synaptic facilitation in rat basolateral amygdala | |
| Yamaoka et al. | Different analgesic effects of adenosine between postoperative and neuropathic pain | |
| RU2008116567A (ru) | Биомаркеры | |
| Vazquez et al. | Local stimulation of the adenosine A2B receptors induces an increased release of IL‐6 in mouse striatum: an in vivo microdialysis study | |
| Jacobsen et al. | Insensitivity of NMRI mice to selective serotonin reuptake inhibitors in the tail suspension test can be reversed by co-treatment with 5-hydroxytryptophan | |
| Banks et al. | Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy | |
| McGaraughty et al. | Antagonism of TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the medial preoptic area of rats | |
| Oluyomi et al. | α‐Adrenoceptor Involvement in Swim Stress‐induced Antinociception in the Mouse | |
| Zhang et al. | Involvement of galanin receptor 2 and CaMKII in galanin-induced antinociception in periaqueductal grey of rats | |
| Bitar et al. | Spinal cord noradrenergic dynamics in diabetic and hypercortisolaemic states | |
| Park et al. | Short-term cold exposure may cause a local decrease of neuropeptide Y in the rat hypothalamus |